|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Prolonged Islet Graft Survival in NOD Mice by Blockade of the CD40-CD154 Pathway of T-Cell Costimulation
From the Diabetes Research Institute (R.D.M., T.B., H.L., P.C., A.P., C.V., N.S.K., C.R., L.I.), University of Miami School of Medicine, Miami, Florida; and Biogen (L.C.B.), Cambridge, Massachusetts.
Address correspondence and reprint requests to Luca Inverardi, MD, Diabetes Research Institute, University of Miami School of Medicine, 1450 NW 10th Ave. (R-134), Miami, FL 33136. E-mail: linverar{at}med.miami.edu .
Allorejection and recurrence of autoimmunity are the major barriers to transplantation of islets of Langerhans for the cure of type 1 diabetes in humans. CD40-CD154 (CD40 ligand) interaction blockade by the use of anti-CD154 monoclonal antibody (mAb) has shown efficacy in preventing allorejection in several models of organ and cell transplantation. Here we report the beneficial effect of the chronic administration of a hamster anti-murine CD154 mAb, MR1, in prolonging islet graft survival in NOD mice. We explored the transplantation of C57BL/6 islets into spontaneously diabetic NOD mice, a combination in which both allogeneic and autoimmune components are implicated in graft loss. Recipients were treated either with an irrelevant control antibody or with MR1. MR1 administration was effective in prolonging allograft survival, but did not provide permanent protection from diabetes recurrence. The autoimmune component of graft loss was studied in spontaneously diabetic NOD mice that received syngeneic islets from young male NOD mice. In this combination, a less dramatic yet substantial delay in diabetes recurrence was observed in the MR1-treated recipients when compared with the control group. Finally, the allogeneic component was explored by transplanting C57BL/6 islets into chemically induced diabetic male NOD mice. In this setting, long-term graft survival (> 100 days) was achieved in MR1-treated mice, whereas control recipients rejected their grafts within 25 days. In conclusion, chronic blockade of CD154 results in permanent protection from allorejection and significantly delays recurrence of diabetes in NOD mice.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M. Phillips, L. O'Reilly, C. Bland, A. K. Foulis, and A. Cooke Patients With Chronic Pancreatitis Have Islet Progenitor Cells in Their Ducts, but Reversal of Overt Diabetes in NOD Mice by Anti-CD3 Shows No Evidence for Islet Regeneration Diabetes, March 1, 2007; 56(3): 634 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Barbe-Tuana, D. Klein, H. Ichii, D. M. Berman, L. Coffey, N. S. Kenyon, C. Ricordi, and R. L. Pastori CD40-CD40 Ligand Interaction Activates Proinflammatory Pathways in Pancreatic Islets Diabetes, September 1, 2006; 55(9): 2437 - 2445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Shi, D. Wang, G. A. Hadley, A. W. Bingaman, S. T. Bartlett, and D. L. Farber Long-Term Islet Graft Survival in NOD Mice by Abrogation of Recurrent Autoimmunity Diabetes, September 1, 2004; 53(9): 2338 - 2345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pearson, P. Weiser, T. G. Markees, D. V. Serreze, L. S. Wicker, L. B. Peterson, A.-M. Cumisky, L. D. Shultz, J. P. Mordes, A. A. Rossini, et al. Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice Is Controlled by Allelic Variants of Idd3 Diabetes, August 1, 2004; 53(8): 1972 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Makhlouf, A. Yamada, T. Ito, R. Abdi, M. J. I. Ansari, C. Q. Khuong, H. J. Winn, H. Auchincloss Jr., and M. H. Sayegh Allorecognition and Effector Pathways of Islet Allograft Rejection in Normal versus Nonobese Diabetic Mice J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2168 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ricordi Lilly Lecture 2002: Islet Transplantation: A Brave New World Diabetes, July 1, 2003; 52(7): 1595 - 1603. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pearson, T. G. Markees, D. V. Serreze, M. A. Pierce, M. P. Marron, L. S. Wicker, L. B. Peterson, L. D. Shultz, J. P. Mordes, A. A. Rossini, et al. Genetic Disassociation of Autoimmunity and Resistance to Costimulation Blockade-Induced Transplantation Tolerance in Nonobese Diabetic Mice J. Immunol., July 1, 2003; 171(1): 185 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Molano, A. Pileggi, T. Berney, R. Poggioli, E. Zahr, R. Oliver, C. Ricordi, D. M. Rothstein, G. P. Basadonna, and L. Inverardi Prolonged Islet Allograft Survival in Diabetic NOD Mice by Targeting CD45RB and CD154 Diabetes, April 1, 2003; 52(4): 957 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pearson, T. G. Markees, L. S. Wicker, D. V. Serreze, L. B. Peterson, J. P. Mordes, A. A. Rossini, and D. L. Greiner NOD Congenic Mice Genetically Protected From Autoimmune Diabetes Remain Resistant to Transplantation Tolerance Induction Diabetes, February 1, 2003; 52(2): 321 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Makhlouf, K. Kishimoto, R. N. Smith, R. Abdi, M. Koulmanda, H. J. Winn, H. Auchincloss Jr, and M. H. Sayegh The Role of Autoimmunity in Islet Allograft Destruction: Major Histocompatibility Complex Class II Matching Is Necessary for Autoimmune Destruction of Allogeneic Islet Transplants After T-Cell Costimulatory Blockade Diabetes, November 1, 2002; 51(11): 3202 - 3210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Wesemann, Y. Dong, G. M. O'Keefe, V. T. Nguyen, and E. N. Benveniste Suppressor of Cytokine Signaling 1 Inhibits Cytokine Induction of CD40 Expression in Macrophages J. Immunol., September 1, 2002; 169(5): 2354 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamada, A. D. Salama, and M. H. Sayegh The Role of Novel T Cell Costimulatory Pathways in Autoimmunity and Transplantation J. Am. Soc. Nephrol., February 1, 2002; 13(2): 559 - 575. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |